Clinical Scorecard: H2-blocker tachyphylaxis may limit LPR therapy

At a Glance

Key Highlights

• Continuous H2-receptor antagonist therapy may lose acid-suppressive efficacy by about day 5; dose escalation does not overcome this loss.
• A cited study found that the initial benefit of adding a bedtime H2-receptor antagonist to PPI therapy for nocturnal acid breakthrough was lost within 1 week, with no sustained gastric pH improvement after 28 days.
• Contemporary gastroenterology guidance supports H2-receptor antagonists mainly for intermittent or as-needed use rather than daily adjunctive therapy.
• Persistent LPR symptoms may reflect nonacid refluxate, laryngeal hypersensitivity, functional laryngeal disorders, or other mechanisms—not necessarily inadequate acid suppression.
• The investigators favor reassessment of persistent symptoms over indefinite escalation of empiric pharmacologic treatment.

Guideline-Based Recommendations

Diagnosis

Management

• The review describes intermittent or as-needed H2-receptor antagonist use as consistent with contemporary gastroenterology guidance, rather than daily adjunctive use.
• Depending on symptom profile and reflux phenotype, the review describes alginates, behavioral or neuromodulatory interventions, and procedural antireflux interventions for selected patients.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients receiving treatment for suspected LPR, including those with persistent symptoms after initial acid-suppressive therapy.

PPIs are commonly used initially for suspected LPR. H2-receptor antagonists are often added or used as alternatives, but continuous use may lose efficacy within days; the review describes intermittent or as-needed use as the contemporary gastroenterology approach.

Clinical Best Practices

• Confirm adherence and dosing when symptoms persist.
• Reconsider the diagnosis and evaluate whether symptoms may involve nonacid reflux or non-reflux mechanisms.
• Consider objective reflux testing when clinically appropriate to characterize acid and nonacid events.
• Avoid indefinite escalation of empiric acid-suppressive treatment without reassessment.
• Reserve procedural antireflux interventions for carefully selected patients with objective evidence of persistent pathologic reflux.

Related Resources & Content

• OTO Open article; source URL not provided